Tachyon Ventures

“At Tachyon, we invest in emerging platforms that shift paradigms — and Stylus represents a major step toward scalable, programmable in vivo gene insertion therapies. We're proud to join a world-class syndicate of co-investors — including RA Capital, Khosla Ventures, and ARCH.”

“At Tachyon, we know how to price scientific risk earlier than others. We maximize upside potential by investing early in disruptive platforms. We mitigate risk by focusing on world-class research with protected IP.”

“Incredibly proud of our Managing Partner Ernest Turro and his team at Department of Genetics and Genomic Sciences at Mount Sinai. This discovery — identifying the most prevalent known recessive neurodevelopmental disorder — will bring diagnostic clarity to tens of thousands of families and opens a clear path toward gene replacement therapies. The kind of science that changes lives.”